ERBB2 and metastatic malignant neoplasm in the lymph nodes: In this study, Her-2 showed an expression sensitivity of 25.51%, and the positive rate of Her-2 expression in patients with different clinical stages and lymph node metastasis is statistically significant (p < 0.05).